A joint study from UCLA and the Veterans Affairs Greater Los Angeles Healthcare System found that the combination of a common nonsteroidal anti-inflammatory drug (NSAID) and an acid-lowering drug is both cost-effective and treatment-effective. The study team compared 3 therapies for treating arthritis: (1) an NSAID, such as ibuprofen or naproxen; (2) an NSAID with an acid-reducer (proton pump inhibitor; PPI), such as lansoprazole (Prevacid) or esomeprazole magnesium (Nexium); and (3) a cyclooxygenase-2 (COX-2) inhibitor, such as rofecoxib (Vioxx) or celecoxib (Celebrex).
The results showed that, for high-risk patients, an OTC NSAID used with a PPI was the safest and most cost-effective treatment. Study author Dr. Brennan Spiegel, codirector of the Center for the Study of Digestive Healthcare Quality and Outcomes, remarked, "COX-2 inhibitors were not a health economic bargain at all-especially given the added costs of more heart attacks."
One study linked multiple pregnancies to an increased risk of developing atrial fibrillation later in life, and another investigated the association between premature delivery and cardiovascular disease.
Clinical features with downloadable PDFs